News & Media

Medical technology company IMRIS Inc. (TSX:IM) booked its first-ever positive results as revenues more than tripled in the fourth quarter.

Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, today announces a non-brokered private placement offering (the “Offering”) of up to 7,150,000 units (“Units”) at

Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce the issuance of Patent No. 2003284385 entitled “Compositions and methods for enzymatic detac

GVI Clinical Development Solutions (GVI-CDS), an innovative CRO focused on quality, timeliness and cost effective services, is pleased to announce that Douglas A. Elliott and Sandra Reis have joined GVI-CDS.

Agreement Includes Fee From Inverness to Acquire Exclusive Option to License Worldwide Rights.

DiaMedica Inc. (TSX-V:DMA) (“Diamedica”), a biopharmaceutical company that has discovered and is developing a novel approach to treating diabetes, announces it has entered into a non-binding letter of intent to acquire all of the issued and outstanding sh

Drug firm concentrates all its work in Manitoba

Winnipeg and the Province of Manitoba will benefit from an initiative to increase local economic activity, thanks to $280,000 in support from the Governments of Canada and Manitoba.

Cangene Corporation today reports financial results for the fiscal year ended July 31, 2009.

Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce that the Company has been selected to present at the Partners in Biomedical Defence 2009 Conf

Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that BioVectra has successfully completed the manufacturing of DispersinB® Topical Wound Gel un

Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce the issuance of Patent No. 7,556,807 entitled “Signal peptides, nucleic acid molecules and me

Winnipeg-based medical device company Intelligent Hospital Systems (IH Systems) was awarded the 21st Century Achievement Award during the Computerworld Honors Program Awards Gala on June 1, 2009 in Washington D.C.

Medicure Inc. ("Medicure" or the "Company") (TSX: MPH) announces its plan to raise up to $3.0 million to improve its financial position through a non-brokered private placement of common shares (the "Offering") at a price of $0.05 per common share.

Company to Receive $467,000 in Funding to Advance Risk Assessment Products for Preeclampsia

The technology, called the AutoLITT System, uses an MRI-guided laser probe, passed through a hole in the skull about the size of a dime, to deliver laser interstitial thermal therapy (LITT) to heat and coagulate the tumour from the inside.

Miraculins Inc. (TSX-V:MOM) (the “Company”), a company focused on developing and commercializing medical diagnostic tests for unmet clinical needs, has closed its previously announced private placement offering (the "Offering") with aggregate gross procee

Medical device company, Intelligent Hospital Systems (IH Systems), has entered into an agreement with the South Korean pharmacy application specialists, Daeiltech (www.daeiltech.co.kr), based in Seoul. Daeiltech will provide direct sales and service suppo

Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms (the “Company”), today announces a non-brokered private placement offering (the “Offering”) for gross proceeds of up

In the arms race between humans and bacteria, the ability to form "biofilms" -- large aggregations of microbes embedded in a slimy matrix -- has been one of the weapons the organisms use to defeat the immune system, antibiotic drugs and other threats. But

Reggie Bowerman saw the doors close at MGI Pharma Inc.’s former headquarters late last year. Now, he’s aiming to open some new doors in biotech for a Canadian startup setting up shop in Minnesota.